Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients
Drug developed by MD Anderson's Therapeutics Discovery division is well-tolerated with effective glutaminase inhibition in Phase I trialCredit: MD Anderson Cancer Center HOUSTON -- The...